F-Prime Capital

F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.

Abdul Abdirahman

Principal

Sanjay Aggarwal

Venture Partner

Jessica Alston

Partner

Nikhil Ananth

Senior Associate

Hannah Arnold

Principal

Raj Basak

Associate

Chu, Kevin

Principal

Lucille Conroy

Senior Associate

Brett Cook

Partner

Jay Farber

Venture Partner

Shervin Ghaemmagham

Operating Partner

Shervin Ghaemmaghami

Investor

Benjamin Gorman

Venture Partner

Ben Gorman

Principal

David Jegen

Managing Partner

Sarah Lamont

Senior Associate

Erica Lee

Senior Associate

Connie Li

Associate

Jon Lim

Partner

Muzammil Mansuri

Venture Partner

Julia McDowell

Venture Partner

Betsy Mulé

Senior Associate

Pasteur Ph.D., Alexander

Partner

Ketan Patel

Partner

Sachin Patodia

Partner

Cameron Raglin

Associate

Brett J. Rome

Venture Partner

Mihir Shah

Venture Partner

Siyu Shi Ph.D

Associate

Nihal Sinha

Principal

Anastasiya Sybirna

Senior Associate

Martin Taylor

Principal

Gaurav Tuli

Partner

Jennifer Uhrig

Senior Managing Director

Bala Varadhan JD

Principal

Robert Weisskoff

Partner

Stacie Weninger

President, FBRI

Alex Wong

Associate

Rocio Wu

Principal

Xu, Chong

Partner

Brian Yordy Ph.D

Principal

Michael Zheng

Venture Partner

Jessica Alston

Principal

469 past transactions

Dinari

Series A in 2025
Dinari is a company that specializes in global employee stock options and incentive management. It provides a comprehensive platform that facilitates equity management and options grants while ensuring compliance with payroll regulations, taxes, and vesting schedules. By enabling investors to gain direct exposure to stock plans and public trading, Dinari simplifies the management of employee incentives, making it easier for organizations to implement effective compensation strategies.

Toku

Series A in 2025
Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.

Galatea Bio

Venture Round in 2025
Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

Bluebird Kids Health

Series A in 2025
Bluebird Kids Health is launching a proprietary technology platform to proactively manage and coordinate treatment, with AI enhancing and simplifying the experience for its clinical team.

Ethena

Funding Round in 2025
Ethena provides derivative infrastructure in order to transform Ethereum into the first crypto-native yield bearing stablecoin.

Eleos Health

Series C in 2025
Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

Rhygaze

Series A in 2025
Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

Tenvie Therapeutics

Series A in 2025
Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

TripSuite

Seed Round in 2024
TripSuite is a venture-backed SaaS startup catering to travel agencies. TripSuite firmly believes that a better world emerges when individuals are exposed to new ideas and cultures through travel experiences. By providing support to travel entrepreneurs and their clientele, TripSuite facilitates enhanced travel opportunities for a broader audience. Their inaugural product streamlines payment processes, making it more efficient and accurate for travel professionals to receive their dues promptly.

Tenpoint Therapeutics

Venture Round in 2024
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals with degenerative ocular diseases. The company's innovative platform focuses on creating treatments that can be delivered directly to the eye, eliminating the need for systemic administration. This targeted approach enhances the potential for effective intervention, allowing healthcare providers to significantly improve the quality of life for patients suffering from various eye conditions. Through its commitment to advancing vision-restoring technologies, Tenpoint Therapeutics is positioned to make a meaningful impact in the field of ocular health.

Albert Invent

Series A in 2024
Albert Invent offers an end-to-end platform that integrates electronic lab notebooks, laboratory information management systems, and AI tools for modern materials science R&D. The platform enhances collaboration, data management, and regulatory compliance while accelerating innovation in chemical research.

Laurus Bio

Venture Round in 2024
Laurus Bio specializes in precision fermentation, providing expertise to clients involved in microbial fermentation-based manufacturing and product development. The company focuses on the production of animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements. Their offerings cater to various sectors, including cultured meat, biologics, vaccine development, and regenerative medicine. By developing novel non-animal origin proteins and media components, Laurus Bio aims to enhance safety, consistency, and traceability in the pharmaceutical and bio-manufacturing industries, enabling clients to create greener and more sustainable healthcare products.

Lighthouse

Series C in 2024
Lighthouse is a commercial platform focused on the travel and hospitality industry, previously known as OTA Insight. The company offers a hotel management platform that visualizes and leverages data to enhance business success. Its cloud-based data intelligence tools provide real-time, actionable insights that empower hoteliers and hotel management companies to make informed revenue and distribution decisions. By facilitating customer support services, Lighthouse helps maximize property occupancy rates and drive revenue growth, transforming complex market conditions into clear, actionable strategies for its clients.

Teleo

Series A in 2024
Teleo specializes in converting existing fleet into supervised autonomous robots. It enables operators to control machines from miles away, instantly switching between machines and across job sites. Teleo increases the operator's productivity, enhances crew safety, and features advanced Jobsite insights.

Zenflow

Series C in 2024
Zenflow, Inc. is a medical device company based in San Francisco, California, that specializes in providing innovative solutions for men suffering from benign prostatic hyperplasia (BPH) symptoms. Founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists, the company aims to address the significant unmet clinical need for effective urinary obstruction treatments. Zenflow's primary product is a spring-like device designed to gently prop open the urethra, restoring its normal function without damaging surrounding tissues. This approach prioritizes patient comfort and minimizes invasiveness, offering a less painful alternative to traditional treatments for urinary obstruction caused by an enlarged prostate.

Notabene

Series B in 2024
Notabene, Inc. is a New York-based company that offers a software as a service (SaaS) platform focused on crypto compliance for the financial industry. Established in 2020, Notabene provides businesses with tools to meet emerging global regulations for cryptocurrency transactions, particularly the Travel Rule. Its platform features a unified API and a comprehensive dashboard designed to assist compliance officers in managing risks associated with both Travel Rule and non-custodial transactions. By simplifying compliance processes, Notabene enables financial companies to engage with a broader range of crypto businesses, enhancing transaction confidence and supporting growth in their operations.

AvenCell

Series B in 2024
Based on our deep science and focused on patients in need.

Shift Bioscience

Seed Round in 2024
Shift Bioscience is focused on using advanced simulation techniques to address the challenges of aging and age-related diseases. The company has developed a high-throughput aging biomarker that facilitates the identification of rejuvenation gene factors through AI-driven cell simulations. By employing deep learning technology, Shift tests extensive gene combinations to discover potential drugs that can reverse aging effects and repair mitochondrial genes. The ultimate goal is to create a single family of drugs capable of treating various diseases associated with aging, thereby promoting sustained health into old age through accessible prescriptions.

Iglu

Seed Round in 2024
Iglu is a software development firm that specializes in facilitating sales and automating business processes through connectivity solutions between various systems and applications. The company's technology offers multiple payment methods and enables integration with ERP systems, functioning as an omnichannel solution that bridges e-commerce and physical retail environments. This comprehensive approach allows retailers to streamline operations and enhance customer experiences across different sales channels.

Spry

Series B in 2024
Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Rippl Care

Series A in 2024
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors affected by dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach that emphasizes personalized care. Rippl Care utilizes innovative technology to deliver comprehensive support, allowing seniors to receive care through various channels, including phone, online, and in-person visits. By focusing on empowering clinicians and adopting a new care model, Rippl Care aims to enhance the quality of life for elderly individuals suffering from conditions such as Alzheimer's disease.

Centivo

Venture Round in 2024
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.

Space and Time

Series A in 2024
Space and Time is a decentralized analytics platform designed to facilitate low-latency queries and tamperproof analytics across the Web. It serves as a multichain data solution for developers and decentralized applications in sectors such as gaming and decentralized finance. The platform enables the integration of on-chain and off-chain data, allowing users to conduct complex queries through a single interface. By transforming major blockchains into advanced databases, Space and Time provides companies with enhanced analytics capabilities, ensuring faster and more reliable insights at an enterprise scale. This innovative approach positions Space and Time as a vital resource for projects requiring next-generation analytics in a decentralized environment.

Canoe

Series C in 2024
Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.

RareCyte

Venture Round in 2024
RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.

Odaseva

Series C in 2024
Odaseva is a company that specializes in data management solutions for large enterprises using Salesforce. Its platform provides comprehensive data governance that focuses on data protection, privacy, and operational efficiency. Key features include backup and recovery, archiving, monitoring of governor limits, and compliance with regulatory requirements such as GDPR. Odaseva's tools enable businesses to manage their Salesforce data effectively, ensuring its confidentiality, integrity, and availability. By offering a range of integrated security products and services, Odaseva empowers organizations to take full control of their data, mitigate risks, and accelerate their digital transformation initiatives.

Canary Technologies

Series C in 2024
Canary Technologies LLC, based in San Francisco, California, specializes in developing innovative software solutions for the hospitality industry, focusing on enhancing operational efficiency and improving guest experiences. The company's platform modernizes outdated hotel management processes by offering features such as contactless check-in, digital authorizations, electronic signatures, and a customizable amenity store. These tools are designed to streamline workflows, reduce costs, increase revenue, and enhance compliance, making them invaluable to hoteliers. Trusted by numerous prestigious hotel brands worldwide, Canary Technologies aims to drive greater productivity and minimize fraud within the sector.

Amber Therapeutics

Series A in 2024
Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system.

Ashby

Series C in 2024
Ashby is a developer of recruitment software specifically designed for high-growth companies. The company offers an enterprise-grade platform that streamlines the hiring process, making it more effective for company leaders, recruiters, and hiring managers. By providing a user-friendly solution, Ashby enables organizations of various sizes to enhance their recruitment strategies and meet their growth objectives more efficiently.

Expressable

Series B in 2024
Expressable is an online speech therapy practice that focuses on enhancing communication for individuals with speech and language disorders, particularly children. By employing a parent-focused care model, Expressable integrates speech therapy techniques into the daily lives of users, thereby improving outcomes and experiences. The platform offers a range of services, including therapy for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. It facilitates consistent practice through weekly activities, enabling users to develop their communication skills effectively.

Quantum Circuits

Venture Round in 2024
Quantum Circuits, Inc. specializes in the development and manufacture of quantum computers utilizing superconducting devices. Founded in 2015 and located in New Haven, Connecticut, the company aims to innovate in the field of quantum computing by delivering full-stack systems that efficiently scale. Led by Dr. Robert Schoelkopf, a prominent figure in quantum science, Quantum Circuits employs a unique dual-rail quantum qubit design that incorporates built-in hardware error detection and conversion. This approach allows for a highly scalable error-corrected system, requiring significantly fewer physical qubits per logical qubit and providing a more efficient pathway to fault-tolerant quantum computing. By focusing on solid-state quantum bits, the company enables clients to perform error-free computations, thereby accelerating research and advancing the practical applications of quantum technology.

Xaira Therapeutics

Venture Round in 2024
Xaira Therapeutics is an integrated biotechnology company focused on revolutionizing drug discovery and development through the application of artificial intelligence. Headquartered in the San Francisco Bay Area, Xaira combines expertise in machine learning, extensive biological and clinical data generation, and robust therapeutic product development. By harnessing advanced AI techniques, the company aims to enhance the understanding of biological processes and improve the effectiveness of therapies. Xaira's approach encompasses all stages of drug discovery, striving to transform how diseases are treated and enabling clients to deliver innovative therapeutic solutions.

Metsera

Series A in 2024
Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Toku

Series A in 2024
Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.

Teleo

Series A in 2024
Teleo specializes in converting existing fleet into supervised autonomous robots. It enables operators to control machines from miles away, instantly switching between machines and across job sites. Teleo increases the operator's productivity, enhances crew safety, and features advanced Jobsite insights.

HiLabs

Series B in 2024
HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. Recognizing that these organizations possess invaluable domain knowledge, HiLabs provides tools that enable them to harness this expertise alongside their data. The platform employs artificial intelligence to allow healthcare professionals to intuitively explore their data, interact with visualizations, customize dashboards, and generate new attributes. This empowers users to independently uncover novel insights and better understand client health data, ultimately facilitating more effective healthcare management and decision-making.

Nocion Therapeutics

Series B in 2024
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.

Comanche Biopharma

Series B in 2024
Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Dispatch

Seed Round in 2024
Dispatch helps independent financial advisors to build ideal firms through strategic investments and advanced technology.

Burro

Series B in 2024
Burro is a developer of an autonomous farming platform designed to enhance productivity in agricultural settings. The company creates robotic tools that autonomously follow workers and transport cargo, alleviating them of physically demanding tasks that do not add significant value. By automating these labor-intensive activities, Burro enables farmworkers to concentrate on more critical functions, ultimately improving operational efficiency. Additionally, the tools capture essential data to facilitate further automation of farm work, aligning with the long-term goal of automating tedious outdoor tasks. Through its innovative approach, Burro aims to support farmers in optimizing their operations and fostering growth.

Genomics

Series C in 2024
Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

OnCusp Therapeutics

Series A in 2024
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments. It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancer patients around the world. It is founded by Bing Yuan, Eric Slosberg, and Andy Fu.

Devoted

Series E in 2023
Devoted Health is a healthcare company focused on enhancing the health and well-being of older Americans by treating each individual with care and compassion. The company offers an integrated healthcare solution that includes Medicare Advantage plans, access to local providers, and the option for virtual and in-home care through Devoted Medical. Their approach includes personalized medical plans and dedicated guides who work closely with physicians to streamline care and minimize unnecessary procedures. By leveraging advanced technology and a robust network of healthcare professionals, Devoted Health aims to provide high-quality, tailored healthcare services to its members.

PlasmaGen Biosciences

Venture Round in 2023
PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy. Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need. They have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology.

Shinobi Therapeutics

Series A in 2023
Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

ARTBIO

Series A in 2023
ARTBIO is a clinical-stage biotechnology company focused on developing innovative alpha radioligand therapies for cancer treatment. By utilizing radioligand therapy, ARTBIO aims to deliver alpha or beta emitters that target and disrupt cancer cell DNA, offering a new approach to oncology. The company is committed to creating a supportive ecosystem that enhances the efficacy of its therapeutics, thereby enabling medical professionals to utilize novel mechanisms in cancer care. Through its advancements, ARTBIO seeks to transform the landscape of cancer treatment and improve patient outcomes.

T-Therapeutics

Series A in 2023
T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

Eleos Health

Series B in 2023
Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

Warmly

Series A in 2023
Warmly, Inc. is a software company that provides an autonomous revenue orchestration platform tailored for small and midsize business (SMB) revenue teams. Established in 2019 and based in Redwood City, California, Warmly's platform utilizes metadata from sales enablement tools, B2B intent data, and enrichment tools to identify and connect with website visitors primed for conversion. By aggregating and integrating insights from various sources, the platform enables users to efficiently track leads, prevent customer churn, cross-sell into new departments, and facilitate warm introductions. This comprehensive approach helps sales teams engage in meaningful conversations with qualified prospects, ultimately enhancing their lead generation and sales effectiveness.

Doceree

Series B in 2023
Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

Nvelop Therapeutics

Seed Round in 2023
Nvelop Therapeutics is engaged in the development of advanced genetic medicines aimed at addressing severe genetic diseases. The company specializes in creating programmable delivery systems that enhance in vivo gene editing and facilitate the delivery of therapeutic cargo. By integrating epigenetic editing technologies with innovative delivery methods, Nvelop Therapeutics targets unmet medical needs, particularly in therapeutically relevant cells and tissues. Their focus on novel gene editing delivery technologies enables medical professionals to effectively deliver a range of therapeutic payloads, thereby improving treatment options for patients suffering from these challenging conditions.

Adela

Series A in 2023
Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Better Life Partners

Series B in 2023
Better Life Partners Inc. is a healthcare provider based in Hanover, New Hampshire, focused on supporting individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners utilizes technology to create personalized care plans that adapt to clients' needs, ensuring effective healthcare delivery through telehealth and community-based solutions. By integrating medical and behavioral healthcare, the company aims to address the complex needs of patients, providing comprehensive support to help them recover from addiction. Better Life Partners has additional offices across various locations in New Hampshire, reflecting its commitment to serving vulnerable populations.

Simon Data

Series D in 2023
Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.

Tenpoint Therapeutics

Series A in 2023
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals with degenerative ocular diseases. The company's innovative platform focuses on creating treatments that can be delivered directly to the eye, eliminating the need for systemic administration. This targeted approach enhances the potential for effective intervention, allowing healthcare providers to significantly improve the quality of life for patients suffering from various eye conditions. Through its commitment to advancing vision-restoring technologies, Tenpoint Therapeutics is positioned to make a meaningful impact in the field of ocular health.

K36 Therapeutics

Series B in 2023
K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

ARTBIO

Seed Round in 2023
ARTBIO is a clinical-stage biotechnology company focused on developing innovative alpha radioligand therapies for cancer treatment. By utilizing radioligand therapy, ARTBIO aims to deliver alpha or beta emitters that target and disrupt cancer cell DNA, offering a new approach to oncology. The company is committed to creating a supportive ecosystem that enhances the efficacy of its therapeutics, thereby enabling medical professionals to utilize novel mechanisms in cancer care. Through its advancements, ARTBIO seeks to transform the landscape of cancer treatment and improve patient outcomes.

Albert Invent

Seed Round in 2023
Albert Invent offers an end-to-end platform that integrates electronic lab notebooks, laboratory information management systems, and AI tools for modern materials science R&D. The platform enhances collaboration, data management, and regulatory compliance while accelerating innovation in chemical research.

BenchSci

Series D in 2023
BenchSci is a developer of a research intelligence platform that leverages advanced artificial intelligence and machine learning to enhance biomedical discoveries. By translating both closed and open-access data into actionable recommendations, BenchSci enables researchers to optimize experiments, particularly in the area of antibody extraction. This innovative approach allows scientists to conduct more successful experiments efficiently, minimizing resource waste and accelerating drug discovery. The company's technology is utilized by pharmaceutical companies and over 4,300 research centers globally, underscoring its significant impact on the scientific community. BenchSci is backed by notable investors, including F-Prime, Gradient Ventures, and Inovia Capital.

BTP Automation

Grant in 2023
BTP Automation specializes in optimizing corporate travel through its advanced hotel sourcing management platform. The company collects and analyzes hotel data from various sources to identify automated cost-saving opportunities. Its technology provides travel buyers with real-time insights into key performance indicators, enhancing the management of hotel programs. By streamlining processes and offering strategic hotel management solutions, BTP Automation enables clients to maximize the value of their travel programs while gaining deeper insights into hotel attachment rates. This focus on business intelligence and analytics helps organizations improve their overall travel efficiency and cost-effectiveness.

Comanche Biopharma

Venture Round in 2023
Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Adcentrx Therapeutics

Series A in 2023
Adcentrx Therapeutics is a biotechnology company dedicated to advancing the development of protein conjugate therapeutics aimed at treating cancer and other serious diseases. The company focuses on creating targeted therapies that leverage the precise targeting capabilities of biologics combined with the therapeutic effectiveness of small molecule payloads. Through its innovative approach, Adcentrx seeks to enhance patient treatment options, offering next-generation therapies that aim to improve outcomes for individuals facing life-threatening conditions.

Tradier

Series B in 2023
Tradier Inc. is a financial services company based in Charlotte, North Carolina, founded in 2014. It operates a cloud-based trading and investing platform designed to enhance trade execution for investors, advisers, and traders. The platform provides access to real-time market data and facilitates seamless account opening and funding. Tradier's innovative solution includes a set of fully hosted APIs, modules, and tools that cater to platform providers and developers, enabling them to create customized financial services. The company is committed to offering transparent pricing and low fees, making it easier for users to engage in trading and investment activities.

1upHealth

Series C in 2023
1upHealth, Inc. operates a health data aggregation and centralization platform that facilitates secure data transmission between health systems and consumer applications. Founded in 2017 and based in Boston, Massachusetts, the company's platform consolidates health data from various electronic medical record systems into a digital health record that users can control and share with their healthcare providers. It also enables providers to access and query up-to-date patient information from multiple connected health systems. Additionally, 1upHealth's platform allows software developers to obtain clinical data from various clinics and hospitals, enhancing the ability to monitor patient activity and automate secure data sharing. By connecting disparate data sources, 1upHealth aims to improve healthcare outcomes for patients while promoting interoperability within the healthcare ecosystem.

Zus Health

Series A in 2023
Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

SpectrumAi

Series A in 2023
SpectrumAi is a digital health company innovating Autism care to increase access to high-quality ABA therapy for kids on the spectrum around the world. With support from industry veterans in technology and healthcare, SpectrumAi is working with global clinical leaders in ABA therapy, parents, and payers to modernize.

Toku

Seed Round in 2023
Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.

TandemAI

Series A in 2023
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

Cadence Neuroscience

Venture Round in 2023
Cadence Neuroscience, Inc. is an early-stage company focused on developing innovative medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company is leveraging core technology developed at the Mayo Clinic, which is currently under clinical evaluation. Cadence's implantable devices are designed to detect specific brain signals and deliver tailored electrical stimulation to modify neural circuit activity. This approach aims to enhance seizure control and improve treatment methods, offering medical practitioners a customizable solution for managing neurological conditions.

Canoe

Series B in 2023
Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.

NOCD

Series B in 2023
NOCD is an online OCD therapy platform that helps people with OCD get better and then stay better. With NOCD, users can have face-to-face video therapy sessions with licensed therapists that specialize in OCD, as well as get 24/7 support between sessions from self-help tools and peer communities.

Enzene Biosciences

Venture Round in 2023
Delivering cost effective biosimilars by developing disruptive technologies, advanced analytics and state-of-the-art manufacturing facility. Being the most desired Biotech company to work for by creating an unparalleled work culture. Broadening the footprint of their innovative technologies through strategic global alliances.

Paradigm

Series A in 2023
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Ensoma

Series B in 2023
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach using Engenious vectors. These vectors are engineered to facilitate the delivery of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the need for stem cell collection or harmful pre-treatment procedures like chemotherapy. This unique capability allows Ensoma to administer therapies through a single injection, making it possible to deliver effective treatments in outpatient settings and areas with limited access to advanced healthcare systems. By streamlining the process of gene therapy, Ensoma aims to enhance the accessibility and curative potential of genomic medicine for patients with various diseases.

Alternative Bio

Seed Round in 2022
Alternative Bio is a biotechnology company focused on developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes.

ABK Biomedical

Series C in 2022
ABK Biomedical combines the clinical market with biomaterials. It specializes in improving treatment options for patients with hypervascular tumors. The company is dedicated to transforming an interventional radiology procedure called embolization.

Pulmocide

Series C in 2022
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Firefly Health

Venture Round in 2022
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Deal Engine

Seed Round in 2022
Deal Engine LLC is a travel software company based in San Francisco, California, founded in 2017. The company specializes in providing solutions that automate various processes within the travel industry using proprietary AI and APIs. By leveraging advanced algorithms for search and booking, Deal Engine aims to reduce corporate travel expenditures by capitalizing on fluctuating pricing. Its platform eliminates manual tasks, allowing corporate travelers and firms to focus on more valuable activities, thereby facilitating digital transformation in the travel sector.

Canary Technologies

Series B in 2022
Canary Technologies LLC, based in San Francisco, California, specializes in developing innovative software solutions for the hospitality industry, focusing on enhancing operational efficiency and improving guest experiences. The company's platform modernizes outdated hotel management processes by offering features such as contactless check-in, digital authorizations, electronic signatures, and a customizable amenity store. These tools are designed to streamline workflows, reduce costs, increase revenue, and enhance compliance, making them invaluable to hoteliers. Trusted by numerous prestigious hotel brands worldwide, Canary Technologies aims to drive greater productivity and minimize fraud within the sector.

ConnexPay

Private Equity Round in 2022
ConnexPay transforms payment acceptance and issuance for Travel and E-commerce providers which act as intermediaries. By offering clients a revolutionary way to minimize risks and reduce credit and debit card acceptance costs through linked real-time payments issued to suppliers, ConnexPay’s clients avoid the need for large lines of credit or personal guarantees. ConnexPay provides a comprehensive, integrated payments solution which incorporates powerful anti-fraud detection along with PCI-certified payment acceptance and payment issuance — driven by ConnexPay’s patent pending intelligent routing and single-use virtual cards — to handle every step of the process. Through a single provider under a simple contract, Travel and E-commerce providers can accept payments from clients and issue payments to suppliers with single-use virtual cards from multiple major card brands. ConnexPay’s advanced solution does not require clients to obtain large lines of credit, provide large reserves, or prepay for most services. Their difference makes all the difference.

Neumora Therapeutics

Series B in 2022
Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

Rippl Care

Seed Round in 2022
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors affected by dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach that emphasizes personalized care. Rippl Care utilizes innovative technology to deliver comprehensive support, allowing seniors to receive care through various channels, including phone, online, and in-person visits. By focusing on empowering clinicians and adopting a new care model, Rippl Care aims to enhance the quality of life for elderly individuals suffering from conditions such as Alzheimer's disease.

Elucidata

Series A in 2022
Elucidata Corporation, founded in 2015 and headquartered in New Delhi, India, specializes in accelerating drug discovery through its proprietary SaaS platform, Polly. This platform transforms drug discovery by delivering machine learning-ready biomedical molecular data, supported by a vast repository of over 230,000 multi-omic datasets, with more than 50,000 datasets added monthly. Polly curates this data semi-automatically, enabling data-driven drug discovery teams to integrate proprietary and public biomedical data for machine learning applications. By adhering to the FAIR guidelines, Polly's Data Lakes provide exclusive access to curated multi-omics data, facilitating faster identification of therapeutic assets with a higher likelihood of clinical success. The platform has proven instrumental in detecting validated drug targets across various fields, including immunology, oncology, and metabolomic disorders. Elucidata collaborates with leading organizations such as Pfizer, Agios Pharmaceuticals, and Genentech, as well as over 35 research partners from prominent biopharma companies and research institutions, enhancing decision-making processes in drug research and development.

Seis

Series A in 2022
Seis is an online banking platform focused on serving Spanish speakers in the United States. The platform provides a range of banking services, including savings accounts, prepaid cards for both online and offline purchases, bill payment solutions, and money transfer options. Seis also offers customizable cards to meet individual preferences and features video and chat-based customer support to enhance the banking experience. Through its comprehensive suite of services, Seis aims to deliver accessible and user-friendly banking solutions to its customers.

Hone

Venture Round in 2022
Hone is a live learning platform for management training that cultivates soft skills with hard data. Hone blends the best of expert-led small group training, peer learning, continuous reinforcement, and a technology platform to develop better leaders, managers, and teammates for today’s workplace. The company's platform helps to expand, connect, and let leaders analyze the impact of the training on the organization to provide improvement for team development. Hone was established in 2018 by Tom Griffiths and Savina Perez in Encinitas, California.

Latchel

Series A in 2022
Latchel, Inc. is a technology company that specializes in providing an online platform for maintenance coordination tailored for property managers and landlords. Founded in 2016 and located in Bellevue, Washington, Latchel's software allows property management companies to efficiently track maintenance requests, select vendors, and enhance tenant satisfaction. The platform facilitates communication between tenants and property managers through a mobile application, enabling residents to schedule maintenance and address tasks promptly. By streamlining operations, Latchel aims to improve net margins for property managers and elevate the overall quality of maintenance services offered to residents.

Spry

Series A in 2022
Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Immuneel Therapeutics

Series A in 2022
Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Vendr

Series B in 2022
Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services, including commercial negotiations, renewal management, and contract logistics. By leveraging a vast dataset from numerous transactions, Vendr empowers finance and procurement teams to make informed decisions, find suitable software solutions, and negotiate fair prices. The platform facilitates the entire purchasing process, from discovering new tools to managing upcoming renewals, thereby helping clients to minimize software expenses. Recently, Vendr raised significant funding and expanded its capabilities through the acquisition of Blissfully, a SaaS management platform.

Proximie

Series C in 2022
Proximie Inc. is a health technology company based in Bedford, Massachusetts, that specializes in a telehealth platform designed for virtual surgical assistance. Founded in 2016 by Nadine Hachach-Haram, Proximie's platform enables surgeons to remotely observe and guide complex surgical procedures using augmented reality, artificial intelligence, and machine learning. This technology allows expert surgeons to connect with their peers globally, sharing knowledge and skills in real-time, regardless of their physical location. The platform is adaptable, compatible with various devices and software used in operating rooms, and can function effectively even in low bandwidth environments. Proximie aims to enhance surgical practices by democratizing access to expert guidance and fostering collaboration among medical professionals.

Peptone

Series A in 2022
Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.

CHARM Therapeutics

Series A in 2022
CHARM Therapeutics is focused on developing innovative medicines using advanced 3D deep learning and drug discovery technologies. The company's platform aims to address undruggable disease targets, providing healthcare professionals with effective treatment options for challenging medical conditions. By leveraging cutting-edge technology, CHARM Therapeutics seeks to create transformative therapies that have the potential to significantly improve patient outcomes.

Teleo

Series A in 2022
Teleo specializes in converting existing fleet into supervised autonomous robots. It enables operators to control machines from miles away, instantly switching between machines and across job sites. Teleo increases the operator's productivity, enhances crew safety, and features advanced Jobsite insights.

SpectrumAi

Seed Round in 2022
SpectrumAi is a digital health company innovating Autism care to increase access to high-quality ABA therapy for kids on the spectrum around the world. With support from industry veterans in technology and healthcare, SpectrumAi is working with global clinical leaders in ABA therapy, parents, and payers to modernize.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.